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http://dx.doi.org/10.1016/j.ccell.2015.06.002SUMMARYEpigenetic dysregulation has emerged as an important mechanism in cancer. Alterations in epigenetic
machinery have become amajor focus for targeted therapies. The current report describes the discovery and
biological activity of a cyclopropylamine containing inhibitor of Lysine Demethylase 1 (LSD1), GSK2879552.
This small molecule is a potent, selective, orally bioavailable, mechanism-based irreversible inactivator of
LSD1. A proliferation screen of cell lines representing a number of tumor types indicated that small cell
lung carcinoma (SCLC) is sensitive to LSD1 inhibition. The subset of SCLC lines and primary samples that
undergo growth inhibition in response to GSK2879552 exhibit DNA hypomethylation of a signature set of
probes, suggesting this may be used as a predictive biomarker of activity.INTRODUCTION
Epigenetic dysregulation is an important mechanism in cancer
initiation and progression (Baylin and Jones, 2011). Machinery
that controls DNA and histone modifications has become a
major focus for targeted therapies (McCabe et al., 2012; Daigle
et al., 2013; Helin and Dhanak, 2013; Knutson et al., 2012; Cope-
land et al., 2013). Lysine demethylase 1 (LSD1) is a histonemodi-
fying enzyme responsible for demethylating histone H3 lysine
4 (H3K4). LSD1 is overexpressed in many human cancers
including lung, breast, prostate, and blood (Serce et al., 2012;
Kahl et al., 2006; reviewed in Lim et al., 2010; Lynch et al.,
2012; Lv et al., 2012). Studies involving knock down of LSD1
have suggested that loss of LSD1 expression reduces the
growth of cancer cells as well as their potential for migration
and invasion (Lv et al., 2012). In acute myeloid leukemia (AML),
LSD1 is most highly expressed in less differentiated subtypesSignificance
SCLC is a highly prevalent, rarely cured tumor type represen
screen of cell lines representing a number of tumor types
GSK2879552. A DNA hypomethylation biomarker identified fro
in response toGSK2879552 correctly predicted sensitivity in pa
anism coupled with a predictive biomarker make LSD1 inhib
is currently in clinical development to investigate the antitumo(Rhodes et al., 2007; Wouters et al., 2009; Radich et al., 2006).
In this setting, knockdown or inhibition of LSD1 had a pro-differ-
entiation effect (Harris et al., 2012) and sensitized AML cells to
all-trans retinoic acid (ATRA), a differentiation therapy used in
acute promyelocytic leukemia (APL) (Schenk et al., 2012). These
studies underscore the important role LSD1 plays in oncogen-
esis and provide evidence that inhibition of LSD1 may offer a
therapeutic strategy for the treatment of cancer.
LSD1 is required for normal differentiation in embryonic as well
as adult cells. Mice with a targeted deletion of LSD1 do not sur-
vive beyond embryonic day 6.5 (Wang et al., 2009a). The activity
of LSD1 is essential for the maintenance of pluripotency in
embryonic stem cells by regulating the balance between H3K4
and H3K27 methylation, thereby keeping differentiation associ-
ated genes silenced (Adamo et al., 2011b). Moreover, LSD1 is
important in enhancer decommissioning when embryonic stem
cells undergo differentiation (Whyte et al., 2012). In the adultting approximately 15% of all lung cancers. A proliferation
indicated that SCLC is sensitive to LSD1 inactivation by
m the subset of SCLC lines that undergo growth inhibition
tient derived xenograftmodels of SCLC. This targetedmech-
ition an exciting potential therapy for SCLC. GSK2879552
r benefit of LSD1 inhibition in SCLC.
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Figure 1. Inactivation of LSD1 by GSK Cyclopropylamine Containing
Inhibitors
(A–C) Structures of GSK2879552 (A), GSK-LSD1 (B), and GSK2699537 (C).
(D) Co-crystal structure of the ligand-binding site of the quaternary complex of
GSK2699537 (gold), FAD (green), and LSD1/CoREST. See also Figure S1 and
Tables S1 and S2.setting, LSD1 is necessary for normal hematopoiesis through
interaction and modulation of GFI1b transcriptional programs
(Saleque et al., 2007) and loss of LSD1 results in impaired hema-
topoiesis through a block in differentiation (Spru¨ssel et al., 2012).
The importance of LSD1 in normal differentiation suggests that
aberrant gene expression resulting from dysregulation of LSD1
may result in alterations in pathways associated with a stem-
cell like phenotype.
Together, the studies in developmental systems and cancer
cells indicate a critical role for LSD1 in stem cell biology and
highlight a potential tumor-promoting effect in cancer. The
current report highlights the discovery and characterization of
targeted inhibitors of LSD1 for clinical development as anti-
cancer therapy.
RESULTS
Discovery and Biochemical Characterization of
LSD1 Inactivators
To discover inhibitors of LSD1, a biochemical assay measuring
LSD1 catalytic activity was used to screen a collection of 2.558 Cancer Cell 28, 57–69, July 13, 2015 ª2015 Elsevier Inc.million compounds. This screen identified a series of small mole-
cule inhibitors that led to the development of GSK2879552,
GSK-LSD1 (publicly available through the Structural Genomics
Consortium: http://www.thesgc.org/chemical-probes/LSD1),
and GSK2699537 (Figures 1A–1C). All three molecules contain
a cyclopropylamine moiety, a functionality that has been utilized
clinically to inactivate the mechanistically related monoamine
oxidases (MAOs) by Parnate (tranylcypromine) in the treatment
of depression (Baker et al., 1992). The predicted mechanism of
inactivation involves single electron reduction of the LSD1-
bound FAD cofactor, leading to homolytic cleavage of the cyclo-
propyl ring, and ultimate covalent modification of the FAD
cofactor (Binda et al., 2010; Schmidt and McCafferty, 2007).
A series of experiments were carried out to confirm the
predicted mechanism of LSD1 inactivation. Kinetic character-
ization of the inhibition of LSD1 by GSK2879552 is consistent
with a reversible binding step followed by time dependent
irreversible inactivation. While the reversible binding affinity is
moderate, complete inactivation of the enzyme is achieved
over time (GSK2879552: LSD1 KI
app = 1.7 ± 0.5 mM, kinact =
0.11 ± 0.01 min1, kinact/ KI
app = 6.47 3 102 ± 3.07 3
103 min1 mM1; Figure S1A; and GSK-LSD1: LSD1 KI
app =
0.16 ± 0.06 mM, kinact = 0.13 ± 0.01 min
1, kinact/ KI
app =
0.81 ± 5.95 3 102 min1 mM1; Figure S1B). Liquid chroma-
tography mass spectrometry (LC-MS) of LSD1 indicated the
protein backbone was not modified by GSK2879552 (Fig-
ure S1C). In contrast, loss of the characteristic UV absorbance
of LSD1-bound FAD was measured, consistent with covalent
modification, while free FAD was unaffected, indicating an
enzyme mediated process (Figure S1D). To confirm the cova-
lent modification of FAD, a high resolution co-crystal structure
was obtained with GSK2699537 (Figures 1D and S1E–S1G;
Table S1). The electron density of the hydroxypropyl benzene
moiety is continuous with the density of FAD, demonstrating
covalent modification. The predicted mechanism of related
cyclopropylamine containing compounds suggests that the
FAD adduct and co-crystal structure would be similar for
GSK-LSD1, as well as the clinical compound GSK2879552.
Together, these studies demonstrate that GSK2879552 and
related analogs are mechanism-based inactivators of LSD1
that require the enzyme’s catalytic machinery to lead to cova-
lent modification of FAD and irreversible inactivation of LSD1.
Prior to additional investigation of the biological mechanism of
action in cells, the selectivity profiles of GSK2879552 and GSK-
LSD1 were assessed. GSK2879552 was evaluated against a
panel of closely related enzymes (LSD2, MAO-A, and MAO-B),
more distantly related FAD dependent enzymes (D-amino acid
oxidase and glutathione reductase), and a non-FAD dependent
oxidase (LoxL2). GSK2879552 was 280-fold selective over
D-amino acid oxidase, the only enzyme sufficiently inhibited to
allow for determination of KI
app and kinact values, allowing for
direct comparison of inactivation efficiency (KI
app = 520 ±
170 mM, kinact = 0.12 ± 0.01 min
1, kinact/ KI
app = 2.3 3 104 ±
1.31 3 105 min1 mM1). Very weak inhibition was observed
against MAO-A and MAO-B, but KI
app and kinact values could
not be calculated. Both molecules were further evaluated in a
panel of G protein coupled receptors, ion channels, nuclear re-
ceptors, kinases, and transporters and were selective against
all proteins tested (Table S2). The selective, potent nature of
GSK2879552 and GSK-LSD1 make these compounds ideal
chemical probes to investigate the biological activity of LSD1.
Both molecules also have good pharmacokinetic properties al-
lowing for use in in vivo studies (Figures S1H and S1I).
Antitumor Effects of LSD1 Inhibition
To elucidate the antitumor activity associated with catalytic inhi-
bition of LSD1, the effect of GSK2879552 treatment was evalu-
ated in 165 cell lines across a range of cancer types. The growth
of 9/28 small cell lung carcinoma (SCLC) lines and 20/29 AML
lines was inhibited by GSK2879552 treatment in a 6-day prolifer-
ation assay (Figures 2A and S2A). In sensitive cell lines, the
magnitude of growth inhibition ranged from 40% to 100% (half
maximal effective concentration [EC50] = 2–240 nM). A similar
profile was observed with the related molecule GSK-LSD1 (Fig-
ure S2B). A few additional cell lines were sensitive to growth in-
hibition by GSK2879552, however, the antiproliferative activity
was largely restricted to SCLC and AML, suggesting these tumor
types have a unique requirement for LSD1.While activity of LSD1
inhibition in AML has been previously reported (Harris et al.,
2012; Schenk et al., 2012), a role for LSD1 in SCLC biology
has not yet been explored. When NCI-H1417 cells were treated
for up to 10 days with GSK2879552, growth inhibition was not
detected until 4 days of treatment, after which dose dependent
antiproliferative activity was apparent (Figure 2B). The delayed
onset of growth inhibition indicates that multiple days of dosing
are required to achieve maximal effects. In a 6-day proliferation
assay, the maximal growth inhibition was largely below 100%,
suggesting the effect was predominantly cytostatic. To confirm
that LSD1 inactivation is not associated with cytotoxicity, cell
cycle analysis and assessment of apoptotic proteins were
performed in multiple SCLC cell lines. Aside from NCI-H1417,
the only line displaying evidence of cytotoxicity, there was no
obvious accumulation of cells in sub-G2 and there were no
apparent changes in caspase-3 or PARP cleavage, indicating
that the majority of cell lines did not undergo a cytotoxic
response to GSK2879552 (Figures S2C–S2E; Table S3). This
largely cytostatic profile is consistent with a pro-differentiation
mechanism as previously reported for LSD1 inhibition in AML
(Harris et al., 2012; Lynch et al., 2012).
LSD1 Inhibition in SCLC
To translate the effects of LSD1 inhibition in vitro to an in vivo
setting, tumor growth inhibition (TGI) was measured in SCLC
xenograft bearing mice orally administered 1.5 mg/kg
GSK2879552 daily. This dose was well tolerated with no body
weight loss or disruption of normal grooming behavior (Figures
S2F and S2G). In toxicology studies conducted in rats and
dogs, the dose limiting effect was severe thrombocytopenia
leading to morbidity (Table S4). Immature hematopoietic cells
were apparent in the bone marrow, consistent with observations
in LSD1 conditional knockout mice (Spru¨ssel et al., 2012). This
effect on platelets was not observed at the dose used in this
study. There was 57% and 83% TGI that was observed in NCI-
H526 and NCI-H1417 tumor bearing mice respectively (Figures
2C and 2D; Table 1). NCI-H510 and NCI-H69 tumor bearing
mice also demonstrated partial TGI (38% and 49% respectively)
in response to GSK2879552, while no significant TGI was
observed for SHP77 bearing mice (Table 1). These results areconsistent with the sensitivity observed in the in vitro proliferation
assay. Interestingly, NCI-H2171 demonstrated a partial TGI
in vivo (Table 1) without obvious sensitivity in the 6-day prolifer-
ation study, raising the potential that the activity profile in SCLC
may be broader than that measured in vitro.
To confirm that LSD1 is expressed and may therefore be a
viable therapeutic target in SCLC, the expression of LSD1 pro-
tein was surveyed. A tissue microarray (TMA) containing 100
formalin fixed paraffin embedded (FFPE) primary human SCLC
samples was evaluated by immunohistochemistry. There was
98 percent of SCLC tumors that demonstrated very high expres-
sion of LSD1 (Figure 2E; Table 2), while a TMA containing 23
samples from various normal human tissue types had low
expression (Table S5).While these data do not eliminate the pos-
sibility that other tumor types may also express high levels of
LSD1, the overexpression in SCLC further implicates LSD1 as
a potential therapeutic target in this tumor type.
SCLC is neuroendocrine in origin, expresses molecular fea-
tures associated with neuroendocrine cells (Park et al., 2011),
has been characterized as a tumor type that is poorly differenti-
ated, and retains stem cell markers such as CD133, Oct4, and
Sal4 (Zhang et al., 2013; Sarvi et al., 2014). LSD1 is implicated
in differentiation in both normal hematopoiesis and in AML,
raising the possibility that efficacy in SCLC is also the result of
inducing differentiation. To investigate the hypothesis that
LSD1 inhibition in SCLC impacts differentiation, the expression
of neuroendocrine marker genes was interrogated in SCLC cell
lines. While there were changes in gene expression of several
neuroendocrine markers in response to GSK2879552, gastrin
releasing peptide (GRP) expression was most consistently
altered across multiple cell lines (Table S6). GRP gene and
pro-GRP protein expression were decreased independent of
sensitivity to GSK2879552 growth inhibition (Figures 3A and
S3A), implying that while altered expression of GRP is a biolog-
ical consequence of LSD1 inhibition, it is not sufficient to confer
an antitumor response. GRP expression was further evaluated
in vivo using NCI-H1417 xenografts. In this setting,GRP expres-
sion was decreased as early as 24 hr post administration in a
dose responsive manner (Figure 3B) and continued to decrease
over time (Figure S3B). The loss of expression of GRP, a marker
that reflects the neuroendocrine origin of SCLC, may indicate an
alteration in the cell state, reminiscent of the pro-differentiation
effect observed in leukemia upon LSD1 inhibition (Harris et al.,
2012).
To further investigate the mechanism of LSD1 efficacy in
SCLC, epigenetic changes in response to GSK2879552 were
evaluated. LSD1 inhibition is predicted to be associated with in-
creases in H3K4 methylation; therefore, changes in the global
levels of H3K4me1 and H3K4me2 were measured by western
blot. While some increases were observed, they were typically
less than 2-fold, indicating that loss of LSD1 activity does not
significantly impact the global levels of H3K4me1 or H3K4me2
(Figures 3C and S3C). Chromatin immunoprecipitation (ChIP)
sequencing studies were utilized to examine the genomic distri-
bution of LSD1 as well as H3K4me2 and H3K4me1 in NCI-H526
cells in the absence and presence of LSD1 inhibition. Analysis of
the average LSD1, H3K4me1, and H3K4me2 density at genomic
regions (gene body ±4,000 bp surrounding transcription start
site [TSS]) revealed enrichment for both histone marks andCancer Cell 28, 57–69, July 13, 2015 ª2015 Elsevier Inc. 59
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Figure 2. LSD1 Expression and Growth Inhibition of SCLC
(A) 165 human cancer cell lines were evaluated for sensitivity to GSK2879552 in a 6-day assay.
(B) Growth inhibition in response to GSK287952 in NCI-H1417 cells.
(C and D) Activity of GSK2879552 on the growth of subcutaneous NCI-H526 (C, TGI = 57%) and NCI-H1417 (D, TGI = 83%) xenografts. The mice were orally
administered 1.5 mg/kg daily and the mean tumor volume ± SEM is shown.
(E) LSD1 protein assessment by IHC. The representative SCLC samples are shown that correspond to each positive signal scored. The degree of LSD1 antibody
reactivity with each tissue section was scored on a scale of 0 (no expression) to 4 (highest expression). The scale bar represents 100 mm. See also Figure S2 and
Tables S3–S5.
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Table 1. Percent TGI
Cell Line Dose (mg/kg)
Mean Tumor
Volume ± SEM (mm3) TGI (%)
NCI-H526 0 (vehicle) 2,359 ± 247 NTa
NCI-H526 1.5 1,113 ± 131 57b
NCI-H526 0.5 1,319 ± 222 48b
NCI-H69 0 (vehicle) 1,063 ± 161 NTa
NCI-H69 1.5 610 ± 131 49b
NCI-H69 0.5 592 ± 130 51
NCI-H510 0 (vehicle) 1,028 ± 182 NTa
NCI-H510 1.5 705 ± 93 38
NCI-H1417 0 (vehicle) 2,262 ± 299 NTa
NCI-H1417 1.5 546 ± 65 83b
SHP77 0 (vehicle) 2,193 ± 293 NTa
SHP77 1.25 1,845 ± 260 17
NCI-H2171 0 (vehicle) 1,553 ± 339 NTa
NCI-H2171 1.25 1,055 ± 222 37
aNT = Not tested.
bp < 0.05.
Table 2. LSD1 Expression in SCLC Tumor Samples Present on
TMA
Number of Cases
Overall Score
% Positive0 1+ 2+ 3+ 4+ > 2
100 2 0 9 34 55 98/100 98%LSD1 at regions within 2,000 bp upstream or downstream of the
TSS (Figure 3D). Local analysis of FEZ1 and IGFBP2 confirmed
enrichment of LSD1, H3K4me1, and H3K4me2 at regions near
the TSS and also revealed enrichment at additional regions distal
to the TSS (Figure 3E). This localization of LSD1 with both of
its histone substrates is consistent with previous studies in em-
bryonic cells (Adamo et al., 2011b; Hnisz et al., 2013; Whyte
et al., 2012). A closer examination of the 1,000 strongest LSD1
peaks from a total of 2,611 genes bound by LSD1 indicated
that these were also enriched for H3K4me1 and H3K4me2 at
regions ±500 bp relative to the LSD1 peak in NCI-H526 cells
(Figure 3F). The Database for Annotation, Visualization, and
Integrated Discovery (DAVID) functional annotation analysis of
the 2,611 LSD1 bound genes revealed that LSD1 is enriched at
genes associated with neuronal differentiation, regulation of
transcription, cell motion, protein amino acid phosphorylation,
cell adhesion, regulation of cell development, embryonic
morphogenesis, and cell-cell signaling (Figure S3D). These find-
ings are consistent with previous reports implicating LSD1 in the
regulation of cell state (Adamo et al., 2011a, 2011b).
Interestingly, catalytic inhibition of LSD1 in NCI-H526 cells
increased enrichment of the protein at genomic regions similar
to those at which it was bound in vehicle treated cells, suggest-
ing that inhibition of LSD1 activity does not result in genomic
redistribution of LSD1 to new sites (Figure 3G). To determine
whether an increase in association of LSD1 was seen at specific
sites, ChIP followed by quantitative PCR (ChIP-qPCR) was used
to validate localization of LSD1 and H3K4 methylation at six
genes identified through ChIP-sequencing in NCI-H526 SCLC
cells. LSD1 ChIP-qPCR demonstrated that the LSD1 protein is
localized to regions surrounding the TSS for all six genes (Fig-
ure 3H). Additionally, all of the putative LSD1 target genes ex-
hibited increased enrichment for H3K4me2 after treatment with
GSK2879552, indicating that inhibition of LSD1 led to increased
H3K4 methylation at genomic loci (Figures 3I, S3E, and S3F).
Treatment with GSK2879552 increased LSD1 signal enrichmentat both SCLC specific typical and super enhancers (Figure 3J),
as previously defined in NCI-H2171 cells (Hnisz et al., 2013).
These results were similar to the effects of LSD1 inhibition
observed on localization of LSD1 at regions near the TSS.
Overall, in SCLC, LSD1 and H3K4 methylation are associated
with regions of chromatin that are implicated in the regulation of
cell state. Inhibition of LSD1 by GSK2879552 increases methyl-
ation and LSD1 enrichment at these sites. These findings are
consistent with studies demonstrating a role for LSD1 in regula-
tion of stemness (Adamo et al., 2011b) and its inhibition in asso-
ciation with a pro-differentiation effect in leukemia (Harris et al.,
2012). While differentiation of SCLC is not well understood,
LSD1 positioning at genes associated with neuronal differentia-
tion and transcriptional regulation may suggest that inhibition
of LSD1 will promote alterations in expression programs associ-
ated with differentiation of this tumor type.
Gene Expression Changes in Response to LSD1
Inhibition in SCLC
LSD1 can remove both di-methyl and mono-methyl marks from
H3K4 (Shi et al., 2004).Methylation ofH3K4 is enriched at regions
surrounding TSS and is associated with actively transcribed
genes (Santos-Rosa et al., 2002; Bernstein et al., 2005). LSD1
is frequently found in transcriptional repressive complexes with
other proteins such as Co-Repressor for Element-1-Silencing
Transcription factor (CoREST) and histone deacetylases
(HDACs) 1 and 2 (You et al., 2001; Shi et al., 2003). Since LSD1
localization and activity correlate with transcriptional repression,
inhibition of LSD1 is expected to result in increased expression of
LSD1 target genes.
To gain additional insight into the mechanism of LSD1 growth
inhibition in SCLC, the effect of GSK2879552 on gene expression
was evaluated in nine SCLC lines, six sensitive to the growth
inhibitory effects of GSK2879552 and three resistant. There
were six of nine that were surveyed at 2, 4, and 7 days of treat-
ment, while all nine cell lines were assessed at 4 days (Figures
4A and S4A), using whole genome microarrays. Expression
changes occurred in both sensitive and resistant cell lines,
but no overt pattern correlated with response. The majority of
changes were increases in expression, consistent with a mecha-
nism involving inhibition of gene repression by LSD1. The early
expression changes were persistent over time (Figure 4B) and
the overall number of changes increased with treatment time in
both sensitive and resistant cell lines (Figure 4A). There was
very little overlap in the upregulated genes or pathways across
cell lines at any time point, precluding the detection of a universal
LSD1 expression signature by microarray analysis (Figure 4C).
As evidenced by the change in GRP expression, a biological
response to LSD1 inhibition was detectable by 24 hr, however,
SCLC cells appeared to require at least 4 days for an apparent
growth response. To further explore the dynamics of LSD1 inhi-
bition, the time course and dose response associated with geneCancer Cell 28, 57–69, July 13, 2015 ª2015 Elsevier Inc. 61
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Figure 3. GSK2879552 Increases H3K4 Methylation Selectively at Genomic Regions Bound by LSD1
(A) SCLC cell lines were treated with 1 mM GSK2879552 for 4 or 7 days. The GRP expression measured by qRT-PCR is shown as percent of expression ± SEM
relative to the vehicle.
(B) GRP expression was measured by qRT-PCR in NCI-H1417 tumors from mice given a single administration of GSK2879552 over a range of doses (EC50 =
0.8 mg/kg) after 24 hr. The values represent mean ± SEM.
(C) Western analysis of global H3K4me1 and H3K4me2 from NCI-H526 cell lysates after 24 hr of treatment with GSK2879552. The recombinant histones with
specific modifications were used as antibody controls. Histone H3 and tubulin were used as the loading controls.
(legend continued on next page)
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expression was evaluated in NCI-H526 cells. Expression of
genes with a range of fold changes revealed by microarray as
well as housekeeping controls were assessed by TaqMan PCR
over a range of time points (days 1, 4, and 7) following treatment
with GSK2879552, aswell as 7 days after washout of compound.
While expression changes could be measured after 1 day, fold
changes continued to increase through days 4–7 for most genes
assessed. The EC50, however, did not change over time (Figures
4D and 4E). Most expression changes began to revert following
compound washout, with significant decreases or near return to
baseline expression at day 14 (Figure 4D).
To correlate TGI observed in xenograft models with
LSD1 dependent gene expression changes, the effects of
GSK2879552 on gene expression were assessed in vivo using
SCLC cell line xenograft models. Treatment with GSK2879552
induced gene expression changes in a dose and time depen-
dent manner in NCI-H526 and NCI-H1417 cells in culture
(Figures 4A–4E and S4B–S4D). Consistent with the cell culture
findings, treatment with GSK2879552 in vivo induced expres-
sion changes in a dose-dependent manner and with greater
fold change after 5 days of treatment relative to 1 day (Figures
4F and S4E). A similar dose response was observed after a sin-
gle administration of GSK2979552 in mice bearing NCI-H1417
xenografts (Figure S4F). Overall, the time dependent gene
expression response suggests that maximal biological effect
requires prolonged exposure to the LSD1 inhibitor. These
data are consistent with the timing of antiproliferative activity
by GSK2879552, indicating that durable inhibition may be
required for therapeutic benefit. The dose response associated
with gene expression indicated that fifty percent of genes that
increased relative to vehicle did so at 1.7 mg/kg. The dose of
1.5 mg/kg was tolerated daily and resulted in TGI in multiple
cell lines, demonstrating that similar doses are required to elicit
gene expression changes and TGI.
Predictive Biomarker of Sensitivity to LSD1 Inhibition
in SCLC
Given that approximately 30% of SCLC cell lines tested were
sensitive to growth inhibition by GSK2879552, genetic, tran-
scriptomic, and DNA methylation profiles were analyzed to
identify potential predictive biomarkers of GSK2879552 sensi-
tivity. Genomic analyses revealed that MYC amplification or
high expression correlated with resistance to GSK2879552 (Fig-
ure S5A). MYCN amplification and high expression correlated
with sensitivity to GSK2879552, however, MYCN amplification
was represented by a relatively small number of cell lines. No(D) Summary plot of LSD1 (red), H3K4me1 (blue), and H3K4me2 (green) enrichm
signal levels.
(E) Genome browser representation of LSD1, H3K4me1, and H3K4me2 binding
(F) H3K4me1 and H3K4me2 levels at strongest LSD1 binding sites ± 5 kb.
(G) Distribution of LSD1 signals in cells treated with 1 mM GSK2879552 (red) or D
(H) LSD1 localization by ChIP-PCR at six putative LSD1 target genes, IgG serv
input ± SEM.
(I) H3K4me2was assessed at six putative LSD1 target genes identified bymicroar
a negative control gene. The values represent the percent of total chromatin inp
(J) Distribution of LSD1 signals at typical (left; p value = 3.483 1034) and super en
cells. The line inside the box shows the median. The bottom and top of the box are
to the most extreme data points which are no more than 1.5 times the interquar
See also Figure S3 and Table S6.correlation was observed between MYCL1 copy number or
mRNA expression and sensitivity to growth inhibition by
GSK2879552. While the different forms of MYC have been
described as having different roles in development and gene
regulation, the specific mechanism by which MYCN and MYC
may have distinct functions in SCLC is poorly understood (Nesbit
et al., 1999). Amplification and/or overexpression of all threemyc
proteins have been described in SCLC tumors and are present in
SCLC cell lines (Peifer et al., 2012; Rudin et al., 2012; Johnson
et al., 1996). Access to a larger panel of primary samples would
be required to further investigate the relationship between
MYCN dysregulation and sensitivity to inactivation of LSD1.
The analysis of global DNA methylation revealed that DNA
hypomethylation correlated with sensitivity to GSK2879552 in
SCLC cell lines (Figure 5A). Based on the methylation patterns
across eight sensitive and 12 resistant cell lines, a regression
model was trained to select a set of probes that predict sensi-
tivity. There were 45 differentially methylated probes that were
identified and were found to be distributed throughout the
genome including promoter, intronic, and intergenic regions
(Figure 5B). Expression of genes corresponding to differentially
methylated probes was surveyed in response to GSK2879552
and, with the exception of MYC and NOD1, were minimally
increased in sensitive relative to resistant SCLC cells (Fig-
ure S5B). The basal expression of genes corresponding to
the differentially methylated probes was evaluated using exist-
ing expression data in SCLC (Rudin et al., 2012). While the
expression of each individual corresponding gene was either
increased or decreased in tumor relative to normal lung, the
overall pattern of expression was consistent across samples
(Figures 5C and S5C).
To determine whether a common mechanism may regulate
the differentially methylated regions, DNA motif analysis was
performed on the associated underlying DNA sequences. This
analysis revealed that SMAD2 binding sequences were enriched
at differentially methylated regions (Figure 5D), potentially impli-
cating the TGF beta pathway in sensitivity to GSK2879552. TGF-
beta signaling is important throughout development and has
been implicated in regulation of lung cancer cell plasticity, linking
this pathway to cellular differentiation (Ischenko et al., 2014).
Specific modulation of TGF-beta signaling in SCLC cells can
inhibit their growth (Nørgaard et al., 1994; Sumitomo et al.,
2000). Analysis of TGF beta pathway associated genes indicated
that this pathway was also strongly dysregulated in SCLC pri-
mary tumors (Rudin et al., 2012) (Figure S5D), however, while
the link to the TGF beta pathway is intriguing, additionalent at TSSs. The y axis denotes normalized LSD1, H3K4me1, and H3K4me2
events at IGFBP2 and FEZ1.
MSO (blue) treated cells.
es as a negative control. The values represent the percent of total chromatin
ray by ChIP-PCR 24 hr after treatment with 1 mMGSK2879552, ACTB serves as
ut ± SEM.
hancers (right; p value = 9.393 105) in 1 mMGSK2879552 and DMSO treated
the first and third quartiles. The lines above and below the box (whiskers) refer
tile range above the upper quartile and below the lower quartile, respectively.
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Figure 4. GSK2879552 Results in Gene Expression Changes across SCLC Cell Lines
(A) Gene expression changes revealed by Affymetrix array analysis in SCLC lines following GSK2879552 treatment following 2, 4, and 7 days of 1 mM
GSK2879552 treatment (p < 0.05,R2-fold change).
(B) Venn diagram showing the overlap of upregulated genes over time in the SCLC line NCI-H526. The values represent the number of probes changed.
(C) Venn diagram showing the overlap of upregulated genes (significant upregulation at any time point) across sensitive cell lines. The values represent the
number of probes changed.
(D) qRT-PCR validation of gene expression changes of ten genes in NCI-H526 cells over a 7 day treatment period with 1 mMGSK2879552. The GSK2879552 was
washed out after the seventh day (*), after which gene expression changes continued to be monitored for an additional 7 days (day 14). The values represent
mean ± SEM.
(E) Dose response associated with GSK2879552-induced IGFBP2 gene expression in NCI-H526 cells treated for 1, 4, and 7 days measured by qRT-PCR.
(F) Gene expression changes were measured by qRT-PCR in NCI-H526 tumors from mice given a single administration of GSK2879552 over a range of doses
after 24 hr. The values represent mean ± SEM. See also Figure S4.exploration in clinical samples will be required to characterize a
link to GSK2879552.
Unsupervised hierarchical clustering analysis revealed that the
differentially methylated probe set might also stratify primary64 Cancer Cell 28, 57–69, July 13, 2015 ª2015 Elsevier Inc.SCLC samples (Figure 5E), indicating its potential utility as a
predictive biomarker. The probe set was further tested and
applied to primary SCLC tumor and patient derived xenograft
(PDX) samples to generate log odds sensitivity scores to predict
Figure 5. SCLC Cell Line Sensitivity to the Antiproliferative Effects of GSK2879552 Is Associated with DNA Hypomethylation
(A) Heatmap of DNAmethylation levels at 45 differentially methylated CpGs associated with sensitivity to GSK2879552. The cell lines and primary SCLC samples
are shown as sensitive (blue), resistant (green), and primary (red).
(B) Genomic distribution of differentially methylated CpGs.
(C) Heatmap shows expression ofmethylation signature genes in primary SCLC tumor and normal lung samples (red: high expression and green: low expression).
(D) DNA motif analysis identified SMAD2 as the most enriched protein of the methylation signature genes (p value = 1 3 1010 Pearson correlation; GSE29422:
Smad2(MAD)/ES-SMAD2-Chip-Seq).
(E) Unsupervised hierarchical clustering of DNA methylation levels of the 45 CpGs in primary SCLC samples. The log odds scores (Figure 6A) are noted above
each sample with blue to yellow range indicating the most resistant to most sensitive prediction. See also Figure S5.sensitivity to LSD1 inhibition (Figures 5E and 6A). There were 18
of 22 samples that were predicted to be sensitive, suggesting
that sensitivity may be more prevalent in primary SCLC relative
to cell lines (Figure 6A). There were three PDX models derived
from primary SCLC tumors (Daniel et al., 2009; Poirier et al.,
2013) that were selected to test the predictive utility of the
DNA methylation signature. There were two of the samples
(LX44 and LX48) that were predicted to be sensitive, while a third
(LX36) was predicted to be resistant (Figure 6A). These PDX
models were assessed for response to LSD1 inhibition. Mice
bearing LX36 xenografts showed no significant TGI, whereas
mice bearing LX44 or LX48 showed 69% and 74% TGI respec-
tively upon daily treatment with 1.5 mg/kg GSK-LSD1 (Figures
6B–6D). The DNA hypomethylation of the signature set identified
in SCLC lines correctly predicted sensitivity to LSD1 inhibitionin primary SCLC, further strengthening the rationale for clinical
application to identify SCLC patients most likely to respond to
GSK2879552 treatment. Additional testing of clinical samples
will be required to strengthen the validity of this predictive
biomarker.
DISCUSSION
The past several years have highlighted the significance of
epigenetic dysregulation in cancer (Baylin and Jones, 2011).
Alterations in the machinery that control the positioning of DNA
and histone modifications have been well described as impor-
tant mechanisms in oncogenesis and have become a major
focus for developing targeted therapies (McCabe et al., 2012;
Daigle et al., 2013; Helin and Dhanak, 2013; Knutson et al.,Cancer Cell 28, 57–69, July 13, 2015 ª2015 Elsevier Inc. 65
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Figure 6. Investigation of DNA Hypomethy-
lation as a Predictive Biomarker of Primary
SCLC Sensitivity to GSK2879552
(A) Prediction scores of sensitivity in primary
tumors. The y axis denotes the log odds scores.
The samples with positive scores are classified as
sensitive and negative scores are classified as
resistant.
(B–D) Activity of GSK-LSD1 on the growth of
subcutaneous primary SCLCmodel LX36 (B, TGI =
19%), LX44 (C, TGI = 69%), and LX48 (D, TGI =
85%). The mice were administered 1.5 mg/kg
daily. The mean tumor volume ± SEM is shown,
*p < 0.05.2012). LSD1 is highly expressed in cancer relative to normal tis-
sue, with a described role in the regulation of differentiation in
AML (Harris et al., 2012; Lynch et al., 2012).
The current report describes the discovery and biological
activity of an inhibitor of LSD1, GSK2879552. This small mole-
cule is a potent, selective, orally bioavailable, mechanism-
based irreversible inactivator of LSD1. A proliferation screen
of cancer cell lines indicated that AML and SCLC were sensitive
to LSD1 inhibition, identifying a role for LSD1 in SCLC. The sub-
set of SCLC cell lines and primary samples that are sensitive
to GSK2879552 can be predicted by a DNA hypomethylation
signature. Together, these data provide strong rationale for
the clinical development of GSK2879552 for the treatment of
SCLC.
GSK2879552 is an irreversible inactivator of LSD1 activity. An
irreversible mechanism of inhibition provides an advantage
in vivo as durable pharmacological inhibition of the target is
maintained beyond time points at which the free inhibitor is pre-
sent. Instead of relying upon the affinity (KI
app) and pharmacoki-
netic (t1/2) properties of the inhibitor, the protein half-life dictates
the duration of inhibition. GSK2879552 is not reactive without
enzyme activation and is highly selective against a panel of
FAD utilizing enzymes, kinases, and other proteins. These prop-
erties make GSK2879552 an ideal small molecule inhibitor for
both investigation of the biological activity of LSD1 in cells as
well as for clinical development.
Given the potential role for LSD1 in cancer, GSK2879552 was
used to test the hypothesis that catalytic inhibition of LSD1 will
result in an antitumor effect. GSK2879552 treatment of a panel
of tumor cell lines indicated that SCLC and AML cells were
uniquely responsive to catalytic inhibition of LSD1. Treatment
of SCLC cells resulted in growth inhibition that was predomi-
nantly cytostatic in vitro and the antitumor response was further
confirmed in vivo. Interestingly, little effect was observed until at
least 4 days of exposure in vitro, indicating that prolonged inhibi-
tion of LSD1 is required for maximal efficacy. This activity profile66 Cancer Cell 28, 57–69, July 13, 2015 ª2015 Elsevier Inc.is consistent with one that would be ex-
pected for an epigenetic agent (McCabe
et al., 2012; Daigle et al., 2013).
SCLC is a tumor type of extremely high
unmet medical need, making this an
intriguing cancer in which to explore the
biological mechanism associated with
GSK2879552 growth inhibition. SCLC isa neuroendocrine tumor and expressesmolecular features asso-
ciated with this cell type. A survey of neuroendocrine marker
genes revealed that while many hallmarks of these cells were
altered in a panel of SCLC lines, GRP was consistently
decreased in response to LSD1 inhibition. Such a change in
neuroendocrine marker expression in SCLCmay reflect an alter-
ation in cell state, a mechanism similar to the observed pro-dif-
ferentiation effect in leukemia upon loss or inhibition of LSD1
(Harris et al., 2012). Pro-differentiation agents have not been
tested to date in SCLC, therefore, GSK2879552 provides an
interesting mechanism of action in a tumor type in which tar-
geted therapies have largely failed (Rodriguez and Lilenbaum,
2010; Sgambato et al., 2013).
GSK2879552 was used to further explore themolecular mech-
anism associated with the antitumor activity of LSD1 inhibition
through studies examining gene expression as well as localiza-
tion of the LSD1 protein. LSD1 inhibition in SCLC cell lines
resulted in altered gene expression in vitro and in vivo in a time
and dose-dependent manner. Similar to the growth inhibition
profile, maximal gene expression fold change required multiple
days of exposure to GSK2879552. Global effects on H3K4
methylation or genomic distribution of LSD1 were not observed,
however, treatment of SCLC cells with GSK2879552 promoted
increased local H3K4 methylation in a manner consistent
with increased transcriptional activation. Interestingly, genes
important for neuron differentiation and cell development were
revealed by gene ontology (GO) analysis of LSD1 ChIP-
sequencing (seq) to be among the most strongly bound by
LSD1, further underscoring a potential role for LSD1 in differen-
tiation of SCLC.
Not all SCLC cell lines tested were sensitive to the antiprolifer-
ative effects of GSK2879552, despite the presence of gene
expression changes. The selective response in 9/28 cell lines in-
dicates that a biomarker of sensitivity may be required to identify
patients likely to respond to LSD1 inhibition. DNA methylation
analyses of SCLC cell lines revealed a differentially methylated
gene signature in sensitive versus resistant lines. The genes that
were differentially methylated shared a motif that corresponded
to SMAD protein binding sites, suggesting a correlation to dysre-
gulated TGF-beta signaling in SCLC tumors. Assessment of
TGF-beta pathway associated gene expression indicated that
it was significantly dysregulated in SCLC tumors relative to
normal lung. While the specific mechanisms surrounding the
role for TGF-beta in SCLCpathogenesis are not well understood,
modulation of TGF-beta signaling (Nørgaard et al., 1994; Sumi-
tomo et al., 2000) can inhibit the growth of SCLC cell lines. More-
over, LSD1 activity has been associated with regulation of TGF-
beta1 in breast cancer (Wang et al., 2009b) and has been impli-
cated in TGF-beta mediated epithelial mesenchymal transition
(EMT) (McDonald et al., 2011). Additional studies will be required
to establish a mechanistic link between TGF-beta signaling and
GSK2879552 activity. The DNA hypomethylation signature iden-
tified in SCLC cell lines was also found in primary SCLC samples.
The utility of this biomarker in predicting sensitivity to LSD1 inhi-
bition was tested in three PDX models and efficacy was
observed only in models with the sensitivity associated DNA
methylation signature. While a mechanistic link between the
methylation status of the signature probe set will require addi-
tional study, the hypomethylation status of this signature set of
probes may allow for the stratification of patients that may
respond to the inhibition of LSD1 by GSK2879552 and provide
a predictive biomarker for use in SCLC.
SCLC accounts for approximately 15% of all lung cancers
and is an extremely aggressive disease with a high rate of
recurrence (Rodriguez and Lilenbaum, 2010). The prognosis
for patients is extremely dismal and there have been no
advances to the current standard of care involving chemo-
therapy combination of platinum and etoposide in almost
30 years. Targeted agents have failed to demonstrate efficacy
to date, further underscoring the critical need for more effective
therapies for this patient population (Sgambato et al., 2013).
GSK2879552 is a small molecule inhibitor of LSD1 with excellent
physicochemical properties that demonstrates efficacy in pre-
clinical models of SCLC. Maximal gene expression responses
and efficacy require durable inhibition, making the irreversible
mechanism of GSK2879552 a significant advantage. Inactiva-
tion of LSD1 provides a targeted mechanism of antitumor
activity in SCLC through promotion of differentiation of this
tumor type enriched in stem-like cells. A DNA hypomethylation
signature may allow for the stratification of patients to best
reveal those that may respond. In summary, GSK2879552
may provide a targeted therapy with a predictive biomarker
strategy for patients with SCLC, a tumor type of extremely
high unmet medical need.
EXPERIMENTAL PROCEDURES
LSD1 Enzyme Assay
LSD1 activity was measured using a horseradish peroxidase (HRP) coupled
assay with amplex red as an electron donor. Details are provided in Supple-
mental Information.
Cell Proliferation Assays
Growth inhibition in response to GSK2879552 was evaluated as previously
described (McCabe et al., 2012). Data were fit with a four-parameter equation
to calculate an EC50 from a concentration response curve.Western Analysis
Whole cell lysates were prepared and analyzed as described in Supplemental
Information.
TMA
SCLC TMA was purchased from Outdo Biotech. Immunohistochemistry was
performed as described in Supplemental Information.
Pro-GRP ELISA
Cells were lysed in 13 cell lysis buffer (Invitrogen #: FNN0021) and sonicated
or, alternatively, a small (100 mg) piece of frozen tumor was removed with a
scalpel from the bulk tumor piece and lysed using a QIAGEN TissueLyser. Ly-
sates were clarified by centrifugation at 10,0003 g for 10min andwere used to
quantitate pro-GRP using the CanAg ProGRP EIA kit (Fujirebio Diagnostics
#220-85) according to the manufacturer’s instructions.
RNA Isolation
Total RNA was isolated using 1 ml TRIzol (Life Technologies #15596-026)
as per the manufacturer’s instructions. For tumor samples, approximately
5–10 mg of tumor tissue was lysed using stainless steel beads (QIAGEN
#69989) and QIAzol Lysis Reagent (QIAGEN #79306). Tissues were processed
by TissueLyser II (QIAGEN) according to manufacturer’s instruction. MaXtract
High Density Tubes (QIAGEN #129056) were used for phase separation. RNA
samples were DNase treated (QIAGEN #79254) and purified according the
manufacturer’s instructions. RNA concentration was determined using a
NanoDrop. TurboCapture 96 Kit (QIAGEN #72251) was used per manufac-
turer’s instructions for gene expression dose response.
RT
Reverse transcription reactions were carried out using a High Capacity cDNA
Synthesis Kit (Applied Biosystems #4374967) according to manufacturer’s
instructions.
PCR
TaqMan PCRwas carried out using 5 ml reactions containing 13 Fast TaqMas-
ter Mix (Life Technologies, Cat #4444964), 0.25 ml Taqman primers, and 2 ml
diluted cDNA. Triplicate PCR reactions were run on ABI ViiA 7 according to
the manufacturer’s instructions. The comparative Ct method using average
2DDCT value for each set of triplicates was calculated, then the average of
the biological replicates was calculated. RT minus were run in a single well
for each TaqMan primer/probe as negative controls. Dose response curves
were generated using XLfit software and EC50 and maximum fold change
values were calculated using a four parameter fit.
ChIP
Cells were crosslinked and chromatin was isolated from nuclear extracts as
described in Supplemental Information. IP was performed using antibodies
as described in Supplemental Information, with constant rotation at 4C over-
night. Protein G: Protein A magnetic beads (Invitrogen, 10003D; 10002D) were
used at 1:4 ratio and blocked in PBS with 0.5% BSA. Beads were added to IP
samples and incubated with rotation at 4C for 3 hr. Beads were collected on
magnetic stand (Invitrogen, 12321D). Washes, elution, and cleanup were
performed as described in Supplemental Information.
Bioinformatics Analyses
Microarray, DNA methylation, and ChIP sequencing methods are detailed in
Supplemental Information. Data are accessible through GEO: GSE66298.
Tumor Growth Assessment
Xenografts were established and tumors were evaluated twice weekly for the
duration of the study as described in Supplemental Information.
All human biological samples were sourced ethically and their research use
was in accord with the terms of the informed consents. The use of human tis-
sue samples was reviewed and approved by GSK Research & Development
Compliance (RDC) Human Biological Sample Use Committee. Animal studies
were conducted in accordance with the GSK Policy on the Care, Welfare, and
Treatment of Laboratory Animals and were approved by the InstitutionalCancer Cell 28, 57–69, July 13, 2015 ª2015 Elsevier Inc. 67
Animal Care and Use Committee either at GSK or by the ethical review process
at Johns Hopkins University.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
five figures, and six tables and can be found with this article online at http://
dx.doi.org/10.1016/j.ccell.2015.06.002.
AUTHOR CONTRIBUTIONS
Conception and design: H.P.M., N.W.J., D.D., P.J.T., R.G.K., and T.K.H.
Development of methodology: N.O.C., C.F.M., N.W.J., G.S.V.A., Y.D., and
H.P.M.
Acquisition of data (provided animals, acquired and managed patients, pro-
vided facilities, etc.): K.N.S., C.D.K., K.E.F., G.S.V.A., J.L.S., J.D.C., Y.L., M.B.,
W.G.B., S.A.G., M.B.P., J.K., X.T., K.C.M., M.R., P.M., T.H., M.C., and H.P.M.
Analysis and interpretation of data (e.g., statistical analysis, biostatistics,
computational analysis): M.T.M., D.S., Y.B., K.N.S., H.P.M., P.M., J.L.S.,
G.S.V.A., K.E.F., M.B.P., and N.O.C.
Writing, review, and/or revision of the manuscript: H.P.M., R.G.K., and
C.L.C.
Study supervision: R.G.K., D.D., P.J.T., N.W.J., C.L.H., W.H.M., and H.P.M.
ACKNOWLEDGMENTS
We would like to thank Craig D. Peacock for assistance in providing samples
for DNA methylation analysis. Authors affiliated with GlaxoSmithKline are
current or previous employees of GlaxoSmithKline. Studies performed at
Johns Hopkins were funded by GlaxoSmithKline, Flight Attendants Medical
Research Institute (FAMRI) Center of Excellence (or Center of Excellence at
Johns Hopkins), and the Alex Grass Foundation.
Received: February 4, 2015
Revised: May 4, 2015
Accepted: June 9, 2015
Published: July 13, 2015
REFERENCES
Adamo, A., Barrero, M.J., and Izpisua Belmonte, J.C. (2011a). LSD1 and plu-
ripotency: a new player in the network. Cell Cycle 10, 3215–3216.
Adamo, A., Sese´, B., Boue, S., Castan˜o, J., Paramonov, I., Barrero, M.J., and
Izpisua Belmonte, J.C. (2011b). LSD1 regulates the balance between self-
renewal and differentiation in human embryonic stem cells. Nat. Cell Biol.
13, 652–659.
Baker, G.B., Coutts, R.T., McKenna, K.F., and Sherry-McKenna, R.L. (1992).
Insights into the mechanisms of action of the MAO inhibitors phenelzine and
tranylcypromine: a review. J. Psychiatry Neurosci. 17, 206–214.
Baylin, S.B., and Jones, P.A. (2011). A decade of exploring the cancer epige-
nome - biological and translational implications. Nat. Rev. Cancer 11, 726–734.
Bernstein, B.E., Kamal, M., Lindblad-Toh, K., Bekiranov, S., Bailey, D.K.,
Huebert, D.J., McMahon, S., Karlsson, E.K., Kulbokas, E.J., 3rd, Gingeras,
T.R., et al. (2005). Genomic maps and comparative analysis of histone modifi-
cations in human and mouse. Cell 120, 169–181.
Binda, C., Valente, S., Romanenghi, M., Pilotto, S., Cirilli, R., Karytinos, A.,
Ciossani, G., Botrugno, O.A., Forneris, F., Tardugno, M., et al. (2010).
Biochemical, structural, and biological evaluation of tranylcypromine deriva-
tives as inhibitors of histone demethylases LSD1 and LSD2. J. Am. Chem.
Soc. 132, 6827–6833.
Copeland, R.A., Moyer, M.P., and Richon, V.M. (2013). Targeting genetic alter-
ations in protein methyltransferases for personalized cancer therapeutics.
Oncogene 32, 939–946.
Daigle, S.R., Olhava, E.J., Therkelsen, C.A., Basavapathruni, A., Jin, L.,
Boriack-Sjodin, P.A., Allain, C.J., Klaus, C.R., Raimondi, A., Scott, M.P.,68 Cancer Cell 28, 57–69, July 13, 2015 ª2015 Elsevier Inc.et al. (2013). Potent inhibition of DOT1L as treatment of MLL-fusion leukemia.
Blood 122, 1017–1025.
Daniel, V.C., Marchionni, L., Hierman, J.S., Rhodes, J.T., Devereux, W.L.,
Rudin, C.M., Yung, R., Parmigiani, G., Dorsch, M., Peacock, C.D., and
Watkins, D.N. (2009). A primary xenograft model of small-cell lung cancer re-
veals irreversible changes in gene expression imposed by culture in vitro.
Cancer Res. 69, 3364–3373.
Harris, W.J., Huang, X., Lynch, J.T., Spencer, G.J., Hitchin, J.R., Li, Y., Ciceri,
F., Blaser, J.G., Greystoke, B.F., Jordan, A.M., et al. (2012). The histone deme-
thylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem
cells. Cancer Cell 21, 473–487.
Helin, K., and Dhanak, D. (2013). Chromatin proteins andmodifications as drug
targets. Nature 502, 480–488.
Hnisz, D., Abraham, B.J., Lee, T.I., Lau, A., Saint-Andre´, V., Sigova, A.A., Hoke,
H.A., and Young, R.A. (2013). Super-enhancers in the control of cell identity
and disease. Cell 155, 934–947.
Ischenko, I., Liu, J., Petrenko, O., and Hayman, M.J. (2014). Transforming
growth factor-beta signaling network regulates plasticity and lineage commit-
ment of lung cancer cells. Cell Death Differ. 21, 1218–1228.
Johnson, B.E., Russell, E., Simmons, A.M., Phelps, R., Steinberg, S.M., Ihde,
D.C., and Gazdar, A.F. (1996). MYC family DNA amplification in 126 tumor cell
lines from patients with small cell lung cancer. J. Cell. Biochem. Suppl. 24,
210–217.
Kahl, P., Gullotti, L., Heukamp, L.C., Wolf, S., Friedrichs, N., Vorreuther, R.,
Solleder, G., Bastian, P.J., Ellinger, J., Metzger, E., et al. (2006). Androgen re-
ceptor coactivators lysine-specific histone demethylase 1 and four and a half
LIM domain protein 2 predict risk of prostate cancer recurrence. Cancer Res.
66, 11341–11347.
Knutson, S.K., Wigle, T.J., Warholic, N.M., Sneeringer, C.J., Allain, C.J., Klaus,
C.R., Sacks, J.D., Raimondi, A., Majer, C.R., Song, J., et al. (2012). A selective
inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells.
Nat. Chem. Biol. 8, 890–896.
Lim, S., Metzger, E., Schu¨le, R., Kirfel, J., and Buettner, R. (2010). Epigenetic
regulation of cancer growth by histone demethylases. Int. J. Cancer 127,
1991–1998.
Lv, T., Yuan, D., Miao, X., Lv, Y., Zhan, P., Shen, X., and Song, Y. (2012).
Over-expression of LSD1 promotes proliferation, migration and invasion in
non-small cell lung cancer. PLoS ONE 7, e35065.
Lynch, J.T., Harris, W.J., and Somervaille, T.C. (2012). LSD1 inhibition: a ther-
apeutic strategy in cancer? Expert Opin. Ther. Targets 16, 1239–1249.
McCabe, M.T., Ott, H.M., Ganji, G., Korenchuk, S., Thompson, C., Van Aller,
G.S., Liu, Y., Graves, A.P., Della Pietra, A., 3rd, Diaz, E., et al. (2012). EZH2
inhibition as a therapeutic strategy for lymphoma with EZH2-activating muta-
tions. Nature 492, 108–112.
McDonald, O.G., Wu, H., Timp, W., Doi, A., and Feinberg, A.P. (2011).
Genome-scale epigenetic reprogramming during epithelial-to-mesenchymal
transition. Nat. Struct. Mol. Biol. 18, 867–874.
Nesbit, C.E., Tersak, J.M., and Prochownik, E.V. (1999). MYC oncogenes and
human neoplastic disease. Oncogene 18, 3004–3016.
Nørgaard, P., Damstrup, L., Rygaard, K., Spang-Thomsen, M., and Skovgaard
Poulsen, H. (1994). Growth suppression by transforming growth factor beta 1
of human small-cell lung cancer cell lines is associated with expression of the
type II receptor. Br. J. Cancer 69, 802–808.
Park, K.S., Liang, M.C., Raiser, D.M., Zamponi, R., Roach, R.R., Curtis, S.J.,
Walton, Z., Schaffer, B.E., Roake, C.M., Zmoos, A.F., et al. (2011).
Characterization of the cell of origin for small cell lung cancer. Cell Cycle 10,
2806–2815.
Peifer, M., Ferna´ndez-Cuesta, L., Sos, M.L., George, J., Seidel, D., Kasper,
L.H., Plenker, D., Leenders, F., Sun, R., Zander, T., et al. (2012). Integrative
genome analyses identify key somatic driver mutations of small-cell lung can-
cer. Nat. Genet. 44, 1104–1110.
Poirier, J.T., Dobromilskaya, I., Moriarty, W.F., Peacock, C.D., Hann, C.L., and
Rudin, C.M. (2013). Selective tropism of Seneca Valley virus for variant sub-
type small cell lung cancer. J. Natl. Cancer Inst. 105, 1059–1065.
Radich, J.P., Dai, H., Mao, M., Oehler, V., Schelter, J., Druker, B., Sawyers, C.,
Shah, N., Stock, W., Willman, C.L., et al. (2006). Gene expression changes
associated with progression and response in chronic myeloid leukemia.
Proc. Natl. Acad. Sci. USA 103, 2794–2799.
Rhodes, D.R., Kalyana-Sundaram, S., Mahavisno, V., Varambally, R., Yu, J.,
Briggs, B.B., Barrette, T.R., Anstet, M.J., Kincead-Beal, C., Kulkarni, P.,
et al. (2007). Oncomine 3.0: genes, pathways, and networks in a collection
of 18,000 cancer gene expression profiles. Neoplasia 9, 166–180.
Rodriguez, E., and Lilenbaum, R.C. (2010). Small cell lung cancer: past, pre-
sent, and future. Curr. Oncol. Rep. 12, 327–334.
Rudin, C.M., Durinck, S., Stawiski, E.W., Poirier, J.T., Modrusan, Z., Shames,
D.S., Bergbower, E.A., Guan, Y., Shin, J., Guillory, J., et al. (2012).
Comprehensive genomic analysis identifies SOX2 as a frequently amplified
gene in small-cell lung cancer. Nat. Genet. 44, 1111–1116.
Saleque, S., Kim, J., Rooke, H.M., and Orkin, S.H. (2007). Epigenetic regula-
tion of hematopoietic differentiation by Gfi-1 and Gfi-1b is mediated by the
cofactors CoREST and LSD1. Mol. Cell 27, 562–572.
Santos-Rosa, H., Schneider, R., Bannister, A.J., Sherriff, J., Bernstein, B.E.,
Emre, N.C., Schreiber, S.L., Mellor, J., and Kouzarides, T. (2002). Active genes
are tri-methylated at K4 of histone H3. Nature 419, 407–411.
Sarvi, S., Mackinnon, A.C., Avlonitis, N., Bradley, M., Rintoul, R.C., Rassl,
D.M., Wang, W., Forbes, S.J., Gregory, C.D., and Sethi, T. (2014). CD133+
cancer stem-like cells in small cell lung cancer are highly tumorigenic and
chemoresistant but sensitive to a novel neuropeptide antagonist. Cancer
Res. 74, 1554–1565.
Schenk, T., Chen, W.C., Go¨llner, S., Howell, L., Jin, L., Hebestreit, K., Klein,
H.U., Popescu, A.C., Burnett, A., Mills, K., et al. (2012). Inhibition of the
LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentia-
tion pathway in acute myeloid leukemia. Nat. Med. 18, 605–611.
Schmidt, D.M., and McCafferty, D.G. (2007). trans-2-Phenylcyclopropylamine
is a mechanism-based inactivator of the histone demethylase LSD1.
Biochemistry 46, 4408–4416.
Serce, N., Gnatzy, A., Steiner, S., Lorenzen, H., Kirfel, J., and Buettner, R.
(2012). Elevated expression of LSD1 (lysine-specific demethylase 1) during
tumour progression from pre-invasive to invasive ductal carcinoma of the
breast. BMC Clin. Pathol. 12, 13.
Sgambato, A., Casaluce, F., Maione, P., Rossi, A., Sacco, P.C., Panzone, F.,
Ciardiello, F., and Gridelli, C. (2013). Medical treatment of small cell lungcancer: state of the art and new development. Expert Opin. Pharmacother.
14, 2019–2031.
Shi, Y., Sawada, J., Sui, G., Affar, B., Whetstine, J.R., Lan, F., Ogawa, H., Luke,
M.P., Nakatani, Y., and Shi, Y. (2003). Coordinated histone modifications
mediated by a CtBP co-repressor complex. Nature 422, 735–738.
Shi, Y., Lan, F., Matson, C., Mulligan, P., Whetstine, J.R., Cole, P.A., Casero,
R.A., and Shi, Y. (2004). Histone demethylation mediated by the nuclear amine
oxidase homolog LSD1. Cell 119, 941–953.
Spru¨ssel, A., Schulte, J.H., Weber, S., Necke, M., Ha¨ndschke, K., Thor, T.,
Pajtler, K.W., Schramm, A., Ko¨nig, K., Diehl, L., et al. (2012). Lysine-specific
demethylase 1 restricts hematopoietic progenitor proliferation and is essential
for terminal differentiation. Leukemia 26, 2039–2051.
Sumitomo, K., Kurisaki, A., Yamakawa, N., Tsuchida, K., Shimizu, E., Sone, S.,
and Sugino, H. (2000). Expression of a TGF-beta1 inducible gene, TSC-36,
causes growth inhibition in human lung cancer cell lines. Cancer Lett. 155,
37–46.
Wang, J., Hevi, S., Kurash, J.K., Lei, H., Gay, F., Bajko, J., Su, H., Sun, W.,
Chang, H., Xu, G., et al. (2009a). The lysine demethylase LSD1 (KDM1) is
required for maintenance of global DNAmethylation. Nat. Genet. 41, 125–129.
Wang, Y., Zhang, H., Chen, Y., Sun, Y., Yang, F., Yu, W., Liang, J., Sun, L.,
Yang, X., Shi, L., et al. (2009b). LSD1 is a subunit of the NuRD complex and
targets the metastasis programs in breast cancer. Cell 138, 660–672.
Whyte, W.A., Bilodeau, S., Orlando, D.A., Hoke, H.A., Frampton, G.M., Foster,
C.T., Cowley, S.M., and Young, R.A. (2012). Enhancer decommissioning by
LSD1 during embryonic stem cell differentiation. Nature 482, 221–225.
Wouters, B.J., Lo¨wenberg, B., Erpelinck-Verschueren, C.A., van Putten, W.L.,
Valk, P.J., and Delwel, R. (2009). Double CEBPA mutations, but not single
CEBPAmutations, define a subgroup of acutemyeloid leukemia with a distinc-
tive gene expression profile that is uniquely associated with a favorable
outcome. Blood 113, 3088–3091.
You, A., Tong, J.K., Grozinger, C.M., and Schreiber, S.L. (2001). CoREST is an
integral component of the CoREST- human histone deacetylase complex.
Proc. Natl. Acad. Sci. USA 98, 1454–1458.
Zhang, Z., Zhou, Y., Qian, H., Shao, G., Lu, X., Chen, Q., Sun, X., Chen, D., Yin,
R., Zhu, H., et al. (2013). Stemness and inducing differentiation of small cell
lung cancer NCI-H446 cells. Cell Death Dis. 4, e633.Cancer Cell 28, 57–69, July 13, 2015 ª2015 Elsevier Inc. 69
